Floatz logo

Evofosfamide

Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

ImmunoGenesisSmall moleculePhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

190 Active assets in the Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Irinotecan
Ipsen
Phase 3BB

View all 50 →

Same molecule, other indications

Evofosfamide is also rated in:

pancreatic neoplasmDormant
B
Indicative ·
56 / 100
View asset →
neuroendocrine neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →